Marklund Marie
Umea University Faculty of Medicine, Department of Odontology, Umea, Sweden.
Turk J Orthod. 2023 Sep 29;36(3):158-164. doi: 10.4274/TurkJOrthod.2022.2022.54.
Discomfort has been related to the poor acceptance of a mandibular advancement device (MAD) in patients with obstructive sleep apnea. The present study compared severe initial side effects between a smaller and a larger degree of mandibular advancement in patients with a good protrusive capacity.
Consecutive patients with obstructive sleep apnea and a good protrusive capacity (≥8 mm) were randomized to start treatment with the mandible advanced by either 70% of maximum protrusion (Adv70%) or by 4 mm (Adv4mm) in a pilot study with a parallel design. The main outcome was tenderness or pain in the teeth or jaws using a 0-10 visual analogue scale (VAS) (from "not at all" to "very extensive") or excluded use because of side effects during the first week of treatment. Secondary outcomes included salivation problems and bite changes.
Eighteen patients were randomly selected and 17 patients fulfilled the study protocol. Four patients in the Adv70% group and none in the Adv4mm group reported severe tenderness or pain (VAS ≥7) on five or more of the seven days (p=0.03). The degree of mandibular advancement measured in millimeters correlated with the number of days with severe side effects, r=0.64 (p=0.006). The secondary side effects were minor.
Starting MAD treatment with 70% mandibular advancement was related to more severe side effects during the first week of treatment compared with a smaller fixed millimeter value in patients with a good protrusive capacity in this pilot study.
在阻塞性睡眠呼吸暂停患者中,不适与下颌前移装置(MAD)的接受度差有关。本研究比较了具有良好前伸能力的患者在较小和较大程度下颌前移时的严重初始副作用。
在一项平行设计的初步研究中,将具有阻塞性睡眠呼吸暂停且前伸能力良好(≥8毫米)的连续患者随机分组,开始使用下颌前移至最大前伸的70%(Adv70%)或前移4毫米(Adv4mm)进行治疗。主要结局是使用0至10的视觉模拟量表(VAS)(从“完全没有”到“非常严重”)评估牙齿或颌骨的压痛或疼痛,或因治疗第一周出现的副作用而排除使用该装置。次要结局包括唾液分泌问题和咬合变化。
随机选择了18名患者,17名患者完成了研究方案。Adv70%组有4名患者,Adv4mm组无患者报告在七天中的五天或更多天出现严重压痛或疼痛(VAS≥7)(p=0.03)。以毫米为单位测量的下颌前移程度与出现严重副作用的天数相关,r=0.64(p=0.006)。次要副作用较小。
在本初步研究中,对于具有良好前伸能力的患者,与较小的固定毫米值相比,以70%下颌前移开始MAD治疗在治疗的第一周会出现更严重的副作用。